Q2 2025 Performance Highlights - Net income increased by 73%[20] - Free cash flow increased by 102%[20] - Earnings per share became positive for the first time[20] Financial Results - Q2 2025 revenue was $27.4 million compared to $28.1 million in Q2 2024[43] - Q2 2025 net income was $2.9 million compared to $1.7 million in Q2 2024[43] - Q2 2025 adjusted EBITDA was $6.5 million compared to $6.4 million in Q2 2024[43] - Q2 2025 earnings per share was $0.04 compared to -$0.14 in Q2 2024[43] - Q2 2025 free cash flow was $5.4 million compared to $2.7 million in Q2 2024[43] - Year-to-date 2025 revenue was $55.0 million compared to $54.1 million in year-to-date 2024[46] - Year-to-date 2025 net income was $4.9 million compared to $1.4 million in year-to-date 2024[46] - Year-to-date 2025 adjusted EBITDA was $12.1 million compared to $10.1 million in year-to-date 2024[46] - Year-to-date 2025 earnings per share was $0.02 compared to -$0.24 in year-to-date 2024[46] - Year-to-date 2025 free cash flow was $9.0 million compared to $4.9 million in year-to-date 2024[46] 2025 Guidance - Revenue guidance is $111 million to $114 million[27] - Adjusted EBITDA guidance is $26 million to $28 million[27] - Earnings per share guidance is $0.10 to $0.13[27]

Financial Performance - Q1 2025 revenue increased by 6.2% year-over-year, from $26 million to $27.6 million[19] - Net income turned around from a loss of $0.24 million in Q1 2024 to a profit of $1.95 million in Q1 2025[19] - Free cash flow increased by 63.6% from $2.2 million in Q1 2024 to $3.6 million in Q1 2025[21] - Adjusted EBITDA increased by 63.6% from $3.6 million in Q1 2024 to $5.6 million in Q1 2025[41] - Adjusted net income increased by 941% from $0.2 million in Q1 2024 to $2.3 million in Q1 2025[41] Strategic Initiatives - The company is focusing on AI-driven solutions to transform healthcare[1,26] - The company launched an AI Center of Excellence in Bagh, targeting 500 AI professionals by year-end[28,29] - The company is expanding its specialty EHR portfolio with a focus on GI and Dermatology[35,36] - The company completed acquisitions of MesaBilling LLC and RevNu Medical Management in early 2025 to enhance client base and expand reach into underserved specialty markets[24] Capital Structure - Post-conversion capital structure shows common equity at 62% and preferred equity at 38%[21] - Pre-conversion capital structure shows common equity at 31% and preferred equity at 69%[21]